Literature DB >> 16279355

Sample size computation for two-sample noninferiority log-rank test.

Sin-Ho Jung1, Sun J Kang, Linda M McCall, Brent Blumenstein.   

Abstract

When an experimental therapy is less extensive, less toxic, or less expensive than a standard therapy, we may want to prove that the former is not worse than the latter through a noninferiority trial. In this article, we discuss a modification of the log-rank test for noninferiority trials with survival endpoint and propose a sample size formula that can be used in designing such trials. Performance of our sample size formula is investigated through simulations. Our formula is applied to design a real clinical trial.

Mesh:

Year:  2005        PMID: 16279355     DOI: 10.1080/10543400500265736

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  9 in total

1.  Rationale and design of the Randomized Evaluation of patients with Stable angina Comparing Utilization of noninvasive Examinations (RESCUE) trial.

Authors:  Arthur E Stillman; Constantine Gatsonis; João A C Lima; William C Black; Jean Cormack; Ilana Gareen; Udo Hoffmann; Tao Liu; Kreton Mavromatis; Mitchell D Schnall; James E Udelson; Pamela K Woodard
Journal:  Am Heart J       Date:  2016-06-17       Impact factor: 4.749

2.  On sample size calculation for comparing survival curves under general hypothesis testing.

Authors:  Sin-Ho Jung; Shein-Chung Chow
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  Parallel-group, randomised, controlled, non-inferiority trial of high-flow nasal cannula versus non-invasive ventilation for emergency patients with acute cardiogenic pulmonary oedema: study protocol.

Authors:  Onlak Ruangsomboon; Nattakarn Praphruetkit; Apichaya Monsomboon
Journal:  BMJ Open       Date:  2022-07-07       Impact factor: 3.006

4.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

5.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

6.  Sample size under the additive hazards model.

Authors:  Lee S McDaniel; Menggang Yu; Rick Chappell
Journal:  Clin Trials       Date:  2015-11-15       Impact factor: 2.486

Review 7.  Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

Authors:  Lindsay A Renfro; Lingyun Ji; Jin Piao; Arzu Onar-Thomas; John A Kairalla; Todd A Alonzo
Journal:  JCO Precis Oncol       Date:  2019-10-24

8.  Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer.

Authors:  Sameer Parpia; Jim A Julian; Lehana Thabane; Chushu Gu; Timothy J Whelan; Mark N Levine
Journal:  BMJ Open       Date:  2014-10-24       Impact factor: 2.692

Review 9.  Design and Analysis of Cancer Clinical Trials for Personalized Medicine.

Authors:  Sin-Ho Jung
Journal:  J Pers Med       Date:  2021-05-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.